Bad medicine?

The article investigates the risks with drugs that are being rushed to market after limited testing. Topics covered are the approval of drugs based on preliminary findings, international ramifications of approvals made by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA), FDA's accelerated approval for bimatorpost for eyelash growth, EMA's granting of conditional marketing authorization to new drugs and expedited approval of cancer drugs.